Brief: Alkermes Announces Positive Topline Results From Enlighten-Early Phase 3B Study Of Lybalvi

Alkermes

08/02/2022 14:30

Feb 8 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES ANNOUNCES POSITIVE TOPLINE RESULTS FROM
ENLIGHTEN-EARLY
PHASE 3B STUDY OF LYBALVI® IN PATIENTS EARLY IN ILLNESS
    * ALKERMES PLC - LYBALVI SHOWED LESS WEIGHT GAIN COMPARED TO
OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOPHRENIFORM
DISORDER OR BIPOLAR I DISORDER
    * ALKERMES PLC - STUDY MET ITS PRE-SPECIFIED PRIMARY
ENDPOINT
    * ALKERMES PLC - FIRST SECONDARY ENDPOINT DID NOT ACHIEVE
PRE-SPECIFIED SIGNIFICANCE LEVEL
    * ALKERMES PLC - NUMERICAL DIFFERENCE WAS OBSERVED BETWEEN
TREATMENT ARMS ACROSS ALL SECONDARY ENDPOINTS IN FAVOR OF
LYBALVI
    * ALKERMES PLC - SAFETY PROFILE OF LYBALVI WAS CONSISTENT
WITH
PREVIOUS STUDIES

Source text for Eikon:  ID:nPreQzKc9a 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))